150 related articles for article (PubMed ID: 1579470)
21. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.
Gandhi V; Legha J; Chen F; Hertel LW; Plunkett W
Cancer Res; 1996 Oct; 56(19):4453-9. PubMed ID: 8813140
[TBL] [Abstract][Full Text] [Related]
22. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
23. The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro.
Lech-Maranda E; Korycka A; Robak T
Haematologica; 2000 Jun; 85(6):588-94. PubMed ID: 10870114
[TBL] [Abstract][Full Text] [Related]
24. Quantification of gemcitabine incorporation into human DNA by LC/MS/MS as a surrogate measure for target engagement.
Wickremsinhe ER; Lutzke BS; Jones BR; Schultz GA; Freeman AB; Pratt SE; Bones AM; Ackermann BL
Anal Chem; 2010 Aug; 82(15):6576-83. PubMed ID: 20698580
[TBL] [Abstract][Full Text] [Related]
25. Cell cycle effects of gemcitabine.
Cappella P; Tomasoni D; Faretta M; Lupi M; Montalenti F; Viale F; Banzato F; D'Incalci M; Ubezio P
Int J Cancer; 2001 Aug; 93(3):401-8. PubMed ID: 11433406
[TBL] [Abstract][Full Text] [Related]
26. Preclinical characteristics of gemcitabine.
Plunkett W; Huang P; Gandhi V
Anticancer Drugs; 1995 Dec; 6 Suppl 6():7-13. PubMed ID: 8718419
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.
Naguib YW; Lansakara-P D; Lashinger LM; Rodriguez BL; Valdes S; Niu M; Aldayel AM; Peng L; Hursting SD; Cui Z
Neoplasia; 2016 Jan; 18(1):33-48. PubMed ID: 26806350
[TBL] [Abstract][Full Text] [Related]
28. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.
Santini V; Bernabei A; Gozzini A; Scappini B; Zoccolante A; D'Ippolito G; Figuccia M; Ferrini PR
Haematologica; 1997; 82(1):11-5. PubMed ID: 9172997
[TBL] [Abstract][Full Text] [Related]
29. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
30. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
[TBL] [Abstract][Full Text] [Related]
31. Alterations in DNA-restriction enzyme interactions by O4-alkyldeoxythymidines.
Richardson FC; Richardson KK
Mol Carcinog; 1991; 4(2):162-8. PubMed ID: 1645973
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
Gontero P; Cattel L; Paone TC; Milla P; Berta G; Fiorito C; Carbone F; Medana C; Tizzani A
BJU Int; 2010 Dec; 106(11):1652-6. PubMed ID: 20590553
[TBL] [Abstract][Full Text] [Related]
33. Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase.
Fowler JD; Brown JA; Johnson KA; Suo Z
J Biol Chem; 2008 May; 283(22):15339-48. PubMed ID: 18378680
[TBL] [Abstract][Full Text] [Related]
34. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
Vande Voorde J; Sabuncuoğlu S; Noppen S; Hofer A; Ranjbarian F; Fieuws S; Balzarini J; Liekens S
J Biol Chem; 2014 May; 289(19):13054-65. PubMed ID: 24668817
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.
Bookman MA
Int J Gynecol Cancer; 2005; 15 Suppl 1():12-7. PubMed ID: 15839953
[TBL] [Abstract][Full Text] [Related]
36. New Mechanism of Gemcitabine and Its Phosphates: DNA Polymerization Disruption via 3'-5' Exonuclease Inhibition.
Yang S; Luo D; Li N; Li C; Tang S; Huang Z
Biochemistry; 2020 Nov; 59(45):4344-4352. PubMed ID: 33147009
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
Heinemann V; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
[TBL] [Abstract][Full Text] [Related]
38. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for topoisomerase I inhibition by nucleoside analogs.
Gmeiner WH; Yu S; Pon RT; Pourquier P; Pommier Y
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):653-8. PubMed ID: 14565246
[TBL] [Abstract][Full Text] [Related]
40. A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-
Sun Y; Wang J; Hao K
Molecules; 2020 May; 25(9):. PubMed ID: 32397338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
